QIAGEN Reports Mixed Q1 2026 Preliminary Results and Updates Full-Year Outlook

Key Facts

1QIAGEN achieved strong profitability as adjusted diluted earnings per share (EPS) met the outlook for the first quarter of 2026.

2Preliminary net sales for Q1 2026 were $492 million, representing a 2% increase on a reported basis.

3Sales trends were impacted by lower QuantiFERON sales and cautious demand from U.S. Life Sciences customers.

QIAGEN N.V. has announced its preliminary financial results for the first quarter of 2026, reporting strong profitability that met previous guidance. Preliminary net sales reached $492 million, marking a 2% increase on a reported basis. While the company successfully met its adjusted diluted earnings per share (EPS) targets, overall sales trends were weighed down by a decline in QuantiFERON sales. Additionally, QIAGEN noted cautious spending patterns among U.S. Life Sciences customers, which impacted regional demand. In light of these mixed results, the company has updated its full-year 2026 outlook to account for current market headwinds. These results highlight a balance between operational efficiency and softening demand in key diagnostic segments.